Perrigo Company plc

Perrigo Company plc PRGO

Dividend Summary

The next Perrigo Company plc dividend is expected to go ex in 22 days and to be paid in 1 month.
The previous Perrigo Company plc dividend was 24c and it went ex 2 months ago and it was paid 1 month ago.
There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 5.1.

Latest Dividends
Summary Previous dividend Next dividend
Status Paid Forecast
Type Quarterly Quarterly
Per share 24c Sign Up Required
Declaration date 28 Jul 2021 (Wed)
Ex-div date 03 Jun 2021 (Thu) 26 Aug 2021 (Thu)
Pay date 22 Jun 2021 (Tue) 14 Sep 2021 (Tue)

Enter the number of Perrigo Company plc shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
95%
Our premium tools have predicted Perrigo Company plc with 95% accuracy.
Dividend Yield Today
1.9%
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for Perrigo Company plc
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
Forecast Quarterly 23 Jul 2025 28 Aug 2025 15 Sep 2025 USD Sign up
Forecast Quarterly 29 May 2025 17 Jun 2025 USD Sign up
Forecast Quarterly 18 Feb 2025 06 Mar 2025 25 Mar 2025 USD Sign up
Forecast Quarterly 17 Oct 2024 28 Nov 2024 17 Dec 2024 USD Sign up
Forecast Quarterly 24 Jul 2024 29 Aug 2024 16 Sep 2024 USD Sign up
Forecast Quarterly 30 May 2024 18 Jun 2024 USD Sign up
Forecast Quarterly 20 Feb 2024 07 Mar 2024 26 Mar 2024 USD Sign up
Forecast Quarterly 19 Oct 2023 30 Nov 2023 19 Dec 2023 USD Sign up
Forecast Quarterly 26 Jul 2023 24 Aug 2023 12 Sep 2023 USD Sign up
Forecast Quarterly 01 Jun 2023 20 Jun 2023 USD Sign up
Forecast Quarterly 21 Feb 2023 09 Mar 2023 28 Mar 2023 USD Sign up
Forecast Quarterly 20 Oct 2022 23 Nov 2022 13 Dec 2022 USD Sign up
Forecast Quarterly 27 Jul 2022 25 Aug 2022 13 Sep 2022 USD Sign up
Forecast Quarterly 02 Jun 2022 21 Jun 2022 USD Sign up
Forecast Quarterly 22 Feb 2022 10 Mar 2022 29 Mar 2022 USD Sign up
Forecast Quarterly 21 Oct 2021 24 Nov 2021 14 Dec 2021 USD Sign up
Forecast Quarterly 28 Jul 2021 26 Aug 2021 14 Sep 2021 USD Sign up
Paid Quarterly 03 Jun 2021 22 Jun 2021 USD 24c 24c 😄
Paid Quarterly 23 Feb 2021 11 Mar 2021 30 Mar 2021 USD 24c 24c 😄
Paid Quarterly 22 Oct 2020 25 Nov 2020 15 Dec 2020 USD 23c 22.5c 😃
Paid Quarterly 29 Jul 2020 27 Aug 2020 15 Sep 2020 USD 23.5c 22.5c 😃
Paid Quarterly 05 May 2020 28 May 2020 16 Jun 2020 USD 24c 22.5c 😊
Paid Quarterly 18 Feb 2020 27 Feb 2020 17 Mar 2020 USD 21c 22.5c 😊
Paid Quarterly 04 Nov 2019 27 Nov 2019 17 Dec 2019 USD 21c 21c 😄
Paid Quarterly 31 Jul 2019 29 Aug 2019 17 Sep 2019 USD 21c
Paid Quarterly 26 Apr 2019 30 May 2019 18 Jun 2019 USD 21c
Paid Quarterly 14 Feb 2019 28 Feb 2019 19 Mar 2019 USD 19c
Paid Quarterly 31 Oct 2018 29 Nov 2018 18 Dec 2018 USD 19c
Paid Quarterly 01 Aug 2018 30 Aug 2018 18 Sep 2018 USD 19c
Paid Quarterly 03 May 2018 31 May 2018 19 Jun 2018 USD 19c
Paid Quarterly 15 Feb 2018 01 Mar 2018 20 Mar 2018 USD 19c
Paid Quarterly 02 Nov 2017 30 Nov 2017 19 Dec 2017 USD 16c
Paid Quarterly 08 Aug 2017 23 Aug 2017 12 Sep 2017 USD 16c
Paid Quarterly 03 May 2017 24 May 2017 13 Jun 2017 USD 16c
Paid Quarterly 21 Feb 2017 01 Mar 2017 21 Mar 2017 USD 16c
Paid Quarterly 08 Nov 2016 22 Nov 2016 13 Dec 2016 USD 14.5c
Paid Quarterly 02 Aug 2016 24 Aug 2016 13 Sep 2016 USD 14.5c
Paid Quarterly 26 Apr 2016 25 May 2016 14 Jun 2016 USD 14.5c
Paid Quarterly 06 Feb 2016 24 Feb 2016 15 Mar 2016 USD 14.5c
Paid Quarterly 04 Nov 2015 24 Nov 2015 15 Dec 2015 USD 12.5c
Paid Quarterly 12 Aug 2015 26 Aug 2015 15 Sep 2015 USD 12.5c
Paid Quarterly 28 Apr 2015 27 May 2015 16 Jun 2015 USD 12.5c
Paid Quarterly 27 Jan 2015 25 Feb 2015 17 Mar 2015 USD 12.5c
Paid Quarterly 03 Nov 2014 25 Nov 2014 16 Dec 2014 USD 10.5c
Paid Quarterly 13 Aug 2014 27 Aug 2014 16 Sep 2014 USD 10.5c
Paid Quarterly 28 Apr 2014 28 May 2014 17 Jun 2014 USD 10.5c
Paid Quarterly 29 Jan 2014 26 Feb 2014 18 Mar 2014 USD 10.5c
Paid Special 07 Dec 2013 19 Dec 2013 USD 1c
Paid Quarterly 06 Nov 2013 26 Nov 2013 17 Dec 2013 USD 9c
Paid Quarterly 14 Aug 2013 28 Aug 2013 17 Sep 2013 USD 9c
Paid Quarterly 02 May 2013 30 May 2013 USD 9c
Paid Quarterly 31 Jan 2013 28 Feb 2013 USD 9c
Paid Quarterly 06 Nov 2012 28 Nov 2012 USD 9c
Paid Quarterly 30 Aug 2012 USD 8c
Paid Quarterly 31 May 2012 USD 8c
Paid Quarterly 01 Mar 2012 USD 8c
Year Amount Change
2006 0.0c
2007 0.0c
0%
2008 0.0c
0%
2009 0.0c
0%
2010 0.0c
0%
2011 0.0c
0%
2012 24.0c
100%
2013 36.0c
50.0%
2014 40.5c
12.5%
2015 48.0c
18.5%
2016 56.0c
16.7%
2017 62.5c
11.6%
2018 73.0c
16.8%
2019 80.0c
9.6%
2020 88.5c
10.6%
2021 Sign Up Required
2022 Sign Up Required
2023 Sign Up Required
2024 Sign Up Required
2025 Sign Up Required

Perrigo Company plc Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
1.9%
Optimized Yield
Sign Up Required
52 Week High
3.7% on 10 March 2021
52 Week Low
1.9% on 28 August 2020
Next Ex-Div-Date Countdown
Sign Up Required

About Perrigo Company plc

Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, incorporated on June 28, 2013, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. The Company manufactures OTC healthcare products and supplies infant formulas for the store brand market. It is also a provider of generic extended topical prescription products. It provides healthcare products across a range of product categories and geographies, primarily in North America, Europe and Australia, as well as in other markets, including Israel and China.

Consumer Healthcare

The Company's CHC segment is focused on the sale of OTC store brand products, including cough, cold, allergy and sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food and diagnostic products. The Company markets in various geographies, including the United States, the United Kingdom and Mexico. Its branded products include the Good Sense, Sergeant's, Sentry, Herron, PetArmor value brands, and the ScarAway brand name.

Branded Consumer Healthcare

The Company's BCH segment develops, manufactures, markets and distributes various European OTC brands in categories, such as natural health, cough, cold and allergy, personal care and derma-therapeutics, lifestyle and pain relief. In addition, the segment manages its regulatory, sales and distribution infrastructure to in-license, and sells non-owned brands and generic pharmaceutical products.

Prescription Pharmaceuticals

The Company's Rx segment develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs for the United States and the United Kingdom markets. It offers a range of topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions and powders. The portfolio also includes select controlled substances, injectables, hormones, women's health products, oral solid dosage forms and oral liquid formulations. Its development areas include other delivery systems, such as oral liquids, metered dose inhalers, injectables and transdermal products. In addition, the Rx segment offers OTC products through the prescription channel (referred to as ORx, these products are marketed using the Perrigo name). ORx products are OTC products that are available for pharmacy fulfillment and healthcare reimbursement when prescribed by a physician. It offers various ORx products that are reimbursable through various health plans and the United States Medicaid and Medicare programs. It manufactures and distributes a range of generic prescription products under various brand names, including Differin, BenzaClin, Entocort, Evoclin, Duac, Olux, Olux-E, Clobex, Desonate, Tridesilon, D.H.E. 45, Ultravate, Bactroban, Mycostatin, Elimite, Klor-Con, Protopic, Androgel, Depo, Testosterone and Triderm/Kenalog.

Specialty Sciences

The Company's Specialty Sciences segment consists of assets focused on the treatment of multiple sclerosis, specifically in connection with the drug, Tysabri (natalizumab). Tysabri also focused on the treatment of Crohn’s diseases.

The Company competes with LNK International, Inc., PL Developments, International Vitamin Corporation, Dr. Reddy's Labs, Johnson & Johnson, Pfizer, Bayer AG, Nestle S.A., Abbott Nutrition, NBTY, Mead Johnson Nutrition Co., Reckitt Benckiser, Boehringer Ingelheim, Novartis, Allergan plc, Apotex Corp., Glenmark Generics Inc., Impax Laboratories, Inc., Mylan N.V., Prasco, LLC, Sandoz, Sun Pharmaceuticals, Taro Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Triax Pharmaceuticals, LLC and Zydus Pharmaceuticals, Inc.

Sector
Pharmaceuticals & Biotechnology
Country
United States
Share Price
$48.71 (yesterday's closing price)
Shares in Issue
136 million
Market Cap
$6.6bn
Dividend Cover
How many times is the dividend covered by company income. A cover of 1 means all income is paid out in dividends
5.1
CADI
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
9
Market Indices
S&P 500
No articles found